Mechanism of Action
Precursor to Endothelin-1
Big ET-1 is cleaved by endothelin-converting enzyme-1 (ECE-1) to produce ET-1 (aa 1-21) and C-terminal fragment (aa 22-38). ET-1 is one of the most potent vasoconstrictors known, acting via ETA and ETB receptors on vascular smooth muscle. Big ET-1 itself binds ET receptors weakly but can be converted to ET-1 locally in tissues, giving it indirect vasoactive effects.
Biomarker Utility
Because big ET-1 is more stable in plasma than ET-1 (which is rapidly cleared), it serves as a surrogate marker for endothelin system activation. Elevated big ET-1 predicts adverse outcomes in heart failure, pulmonary arterial hypertension, acute myocardial infarction, and sepsis. It is included in multiplex cardiovascular biomarker panels.
Research Summary
Cardiovascular Biomarker
Clinical EvidenceMultiple prospective studies show that big ET-1 measured in plasma predicts mortality in acute heart failure and acute coronary syndrome independently of BNP/NT-proBNP. The CHARM trial and CORONA trial both validated big ET-1 as a prognostic marker. Its relative plasma stability vs ET-1 makes it analytically easier to measure.
Pulmonary Hypertension
Clinical EvidenceEndothelin receptor antagonists (bosentan, ambrisentan, macitentan) are approved for pulmonary arterial hypertension (PAH). Big ET-1 levels correlate with PAH severity and decline with effective treatment. It has been proposed as a monitoring biomarker for ERA therapy response.
ECE Inhibition
PreclinicalBlocking ECE-1 to prevent big ET-1 conversion to ET-1 is a potential therapeutic strategy. Preclinical ECE inhibitors reduce vascular tone in hypertensive models. Clinical development has been limited by isoform selectivity challenges and side effects.
Calculate your Big Endothelin-1 dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Biomarker measurement | N/A | Plasma draw at baseline/follow-up | Blood draw (ELISA/immunoassay) |
| ECE inhibition (rodent) | ECE inhibitor co-administration | Varies by compound | Oral/IV |
| Endothelin system activation model | 1-10 pmol/kg IV | Single bolus | Intravenous |
Big ET-1 itself is not administered therapeutically. Its primary research and clinical utility is as a plasma biomarker.
Interactions
Safety Profile
Big ET-1 is not administered as a therapeutic agent. As a biomarker molecule, its clinical relevance is in measurement, not administration. Elevated endogenous big ET-1 is associated with adverse cardiovascular outcomes. The endothelin system as a therapeutic target has been validated by approved ERAs, which have class-specific side effects including hepatotoxicity (class warning) and peripheral edema.
References
- [1]Yanagisawa M, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332(6163):411-415.
- [2]Pousset F, et al. Prognostic value of plasma endothelin-1 in patients with chronic heart failure. Eur Heart J. 1997;18(2):254-258.
- [3]Levin ER. Endothelins. N Engl J Med. 1995;333(6):356-363.